INTRODUCTION
The first rate limiting step of kynurenine pathway is the catabolism of tryptophan (L-TRP) to N-formyl kynurenine which is take place in the presence of haem containing enzyme indoleamine 2,3-dioxygenase (IDO) (Sono et al., 1996) . IDO is usually found in the tissues, such as neuroglia, macrophages of the central nervous system in mammals (Botting, 1995) . The activity of IDO is regulated by cytokines. Pro inflammatory cytokines such as Interferongamma, interlukin-1 or tumor necrosis factor -α are potent inducers of IDO, however anti-inflammatory cytokines such as interlukin-4 and interlukin-10 are IDO inhibitors (Weiss et al., 1999) . Besides interferon-gamma and tumor necrosis factor -α, other pro inflammatory molecules such as prostaglandin E2 (PGE2) synergistically induce an increase of IDO activity (Braun et al., 2005 , Kwidzinski et al., 2005 and Robinson et al., 2005 . In inflammation the link between immune system and kynurenine pathway play an important role. An infectious microbe such as bacteria depends on TRP for their survival and the ingestion of tryptophan play a crucial role during infectious diseases (Carlin et al., 1989 and Grohmann et al., 2003) . In serotonin synthesis pathway the availability of TRP is the rate limiting factor. So, the induction of IDO by cytokines decreases the availability of TRP for serotonin synthesis (Mellor and Munn ,1999; Munn et al., 1999) . Mostly IDO is expressed in many cancers like gastric, pancreatic, colorectal and prostate cancers (Uyttenhove, 2003) , ovarian cancer (Tanazaki et al, 2014) . The most common complication of cancer is cancer related fatigue (CRF) and its treatment that can significantly impair quality of life. However, the actual mechanisms remain understood, now the inflammation is supposed to be an important factor of CRF in addition to effects of depression, anxiety, insomnia, and other factors. One key biological pathway that may link inflammation and CRF is indoleamine 2,3-dioxygenase (Kim et al, 2015) . Since 1990s Hypericum perforatum (HP), is also referred to as St. John's wort, has been clinically approved herbal medicine (Roder et al., 2004) . As yet species of hypericum family plant have potential medicinal value. HP has anti-depression, anti-viral and anti-inflammatory activities. Previous studies by Hammer et al. (2007) showed that different doses of HP extracts inhibit prostaglandin E2 production through lipopolysaccharide (LPS)-induction. Currently SJW is used in treating eczema, inflammation related disorders, cancer, burns, viral and bacterial disease and also researcher proved its effect as an antioxidant and neuroprotective agent (Klemow, 2011) .
IDO is an important therapeutic target for the treatment of above mention disease. We can overcome this problem by finding the inhibitors of this enzyme. Until, the best known IDO inhibitors are 1MT (Sono and Cady et al., 1991) , ß-Carboline (Eguchi et al., 1984) . In 2006, effective nano molar inhibitors were isolated from marine invertebrates extract (Brastiano et al., 2006 and Pereria et al., 2006) . Simultaneously new brassinin based IDO inhibitors were published (Banerjee et al., 2008 , Gaspari 2006 . In this work we have selected one structure hits of protein from protein data bank (PDB) overly expressing in disease. The docking of HP with IDO has not yet been done. Therefore, we performed docking against single crystal structure of IDO further we analyzed the acute and chronic effects of HP on IDO enzyme activity after administration.
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Computational studies
Molegro Virtual Docker was used to perform docking. HP was selected for this study. The selected ligands structure was built using ChemDraw ( Figure 1 ) software and imported to MVD workspace in 'sdf' format. All necessary valency checks and H atom addition were thus performed using the utilities provided in MVD. The crystal structure selected for this study is IDO complex with phenyl imidizol (PIM) (Figure 2 ), from the available 2 crystal structures (July 2014 Drug preparation 500 mg/kg/3 ml of HP were dissolved in vehicle (1 ml ethanol: 2 ml saline). Drug was administered according to the body weight of rats.
Animals and treatment
Locally bred male Albino Wistar rats (150-250 gm body weight) were used in this investigation. Animals were kept in plastic cages under natural light dark cycle at room temperature 25±2°C. The animals had free access of food and water and were acclimatized to their environment before any treatment of experiment. Animals were divided into different groups. Each groups had six rats. Test animals received HP (500 mg/kg/3ml) and control rats received 3 ml vehicle (ethanol: saline) (1:3 v/v) by oral gavage and were decapitated after 3.5 hrs and after 7 days treatment respectively.
Enzymatic determination
Frozen brain samples were weighted and homogenized for one minute using Ultra-Turrax homogenizer in ice-cold water and 12% (w/v) HClO4. Volumes of water and HClO4 were used as I gm tissue add 1 ml water and 2 ml HClO4. The homogenates were kept in ice-cold tubes for 10 min then centrifuged at 6000 rpm for 10 min at 4°C. The supernatants were poured and volume was adjusted to 4 ml with 6 % (w/v) HClO4. A 0.5 ml portion of each homogenate was filtered and used or stored. IDO activity was determined by calculating KYN/TRP ratio in serum and brain as described by (Badawy and Morgan, 2010) .
Preparation of serum extract
To each ice-cold 1 ml Eppendorf tube, add 0.5 ml (500µL) of the plasma or serum sample and 0.45 ml (450µL) of HPLC-grade water. Add 50 µL of 60% HClO4 and vortex for 5-10 seconds. Allow to stand at room temperature (still in the ice-cooled rack) for 5 minutes. Spin in a high-speed centrifuge at 8000 rpm at 4°C for 10 minutes. Decant the supernatant carefully into another Eppendorf tube and make it up to the 1 ml mark with 6% HClO4. Store in the freezer, or, if to be used freshly, then; filter 0.5 ml in a Vectaspin tube at 8000 rpm in a high-speed refrigerated centrifuge at 4°C for 10 min. Transfer the filtrate into an HPLC vial using a pasteure pipette. Serum TRP and KYN concentration were determined by HPLC method of Badawy and Morgan (2010) .
(1R,5S,6R,7S)-4-hydroxy-6-methyl-1,3,7-tris(3-methylbut-2-en-1-yl)-6-(4-methylpent-3-en-1-yl)-5-(2-methylpropanoyl)bicyclo[3.3.1]non-3-ene-2,9-dionemethylpropanoyl)bicyclo[3.3.1]non-3-ene-2,9-dione 
Statistical analysis
Data are expressed as mean ± standard error of mean. Analysis was performed by using one-way ANOVA followed by Tukey's test for stepwise comparison between the individual values. Difference between the two groups were considered significant when P<0.05.
RESULTS
Mol Dock score and H-bond energies when HP were dock against IDO Table 1 shows Mol Dock score, re-rank score and the hydrogen bond energy of selected ligand. Table 2 shows amino acid residues present in the active site of IDO and also ligand binding amino acids. Figure 1 shows selected ligand structures were built using ChemDraw software. 
Experimental studies Acute and chronic effects of HP on serum indoleamine 2,3-dioxygenase activity
RESULTS
chronic treated rats when compared with saline control. Table also shows there were significantly increased serum KYN/TRP ratio (171%, P<0.01) and (114%, P<0.01) in acute and chronic rats when compared with saline control.
Acute and chronic effects of HP (500mg/kg) on brain indoleamine 2,3-dioxygenase activity Table 4 shows effects of HP (500mg/kg/3ml) on TRP and KYN. Data analyzed by one-way ANOVA shows significant effect of drug (F=27.6, P<0.01, F=53.95 F=113.4,P<0.01) on brain TRP, KYN and KYN/TRP ratio. Individual comparison by Tukey's test shows that there were significantly increased brain TRP (31.2%, P<0.01) and (71.8%, P<0.01) respectively in acute and chronic treated rats when compared with saline treated rats. Table also shows there were significantly increased brain KYN (30.5%, P<0.01) in acute rats while no significant effect was observed in chronic treated rats when compared with saline injected control rats. Table  also shows that there were significantly decreased (42%, P<0.01 and 43%, P<0.01) brain KYN/TRP ratio respectively in acute and chronic treated rats when compared saline control rats.
DISCUSSION
The enzyme IDO plays a physiologically important role in the human body as it can control the levels of essential amino acid (L-Tryptophan), and a number of its neurotoxic metabolites. IDO is frequently expressed in many cancers such as gastric, pancreatic, colorectal and prostate cancers (Uyttenhove, 2003) , ovarian cancer (Tanazaki et al, 2014) and inflammation (Kim, 2015) . To identify IDO inhibitors for therapeutic purpose we have selected IDO protein. For this purpose, IDO was docked with HP. In each docking run, the best poses were selected on the basis of their MVD score. As previously described, ligand was automated dock within the defined grid representation after docking a score was assigned according to the quality of fit and top ten candidate were selected on the basis of exhibiting lowest predicted binding energy. This ligand was further optimized according to their energy minimization active side chain residue.
More negative the energy score (Kcal/mol) more is the binding affinity. Energy scores of HP is -158.687 K cal/mol this data also indicates that by additionally optimization these possible ligands can make a strong therapeutic inhibitor of IDO enzyme. In the reported crystal structure of IDO, PIM interacts with the haem iron, PIM binding site consist of amino acid residues Tyr126, Cys 129, Val 130, Phe 163, Phe 164, Ser 167, Leu234, Gly 262, Ser 263, Ala 264 and the haem ring ( Figure 4C ). Additional hydrogen bond is possible due to side chain of Arg 231. Haem ring and Phe 163, Phe 226, Leu 234, Ile 354 formed hydrophobic pocket (pocket B, Figure 4b ) (Dolusic et al., 2011) . HP binding site consist of amino acid residue Glu 119, Arg 256, Thr 282, Val 275, Gln 280,281, Ser 315. HP binds with IDO at allosteric site.
In vivo IDO activity can be measured by calculating the proportion of product:substrate (KYN/TRP). Therefore, an increase in the ratio will enhance the enzyme activity and a decrease in ratio will decline the enzyme activity. In the present study acute and chronic treatment with HP decreased serum total TRP while increased serum KYN and KYN/TRP ratio which reflect the induction of IDO. In contrast brain TRP level significantly increased and decreased level of KYN and KYN/TRP ratio which reflect the inhibition of brain IDO following single and chronic dose of HP.
In the present study, HP induce serum IDO while inhibit the brain IDO which shows that mode of action of HP is different in different tissue. Previously it has been reported by (Wesam et al., 2014) that HP decreased the levels of hippocampal TNF-α, and corticosterone in the serum. We have also found increased level of brain TRP and decreased level of brain KYN and KYN/TRP ratio which is consistent with (Wesam et al., 2014) who has found significant decreases in TRP and KYN level but insignificant effect on hippocampus KYN/TRP in response to acute treatment following different doses. In another experiment Calapai and coworker, (2001) have showed that higher doses of (250-500 mg/kg) SJW given orally to the rats has significantly increased the levels of serotonin, norepinephrine and dopamine content in brain which decreases immobility time in forced swim stress. Previously we (Bano and Dawood, 2008) have also reported anxiolytic property of SJW, that increases serotonin metabolism in neuron but reduce its release under adverse conditions and serotonergic variations in swim stressed rats (Ara and Bano, 2009) . It has been also reported that 10 mg SJW inhibit TDO increased serum free TRP and serum corticosterone and enhance brain TRP and serotonin level (Bano et al., 2010) .
CONCLUSION
It is concluded that HP is possible lead molecules having their highest docking score. Present results also proof HP is noncompetitive inhibitor of IDO. It is concluded that administration of HP inhibit brain IDO activity could contribute in its anti-inflammatory effect.
